Related Experiment Video
Updated: Mar 7, 2026
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
Published on: October 20, 2015
Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine
Cory M Hugen1, Daniel E Zainfeld1, Amir Goldkorn2
1Keck School of Medicine and Norris Comprehensive Cancer Center, Urology , Los Angeles, CA , USA.
Abstract:
Precision medicine with molecularly directed therapeutics is rapidly expanding in all subspecialties of oncology. Molecular analysis and treatment monitoring require tumor tissue, but resections or biopsies are not always feasible due to tumor location, patient safety, and cost. Circulating tumor cells (CTCs) offer a safe, low-cost, and repeatable tissue source as an alternative to invasive biopsies. "Liquid biopsies" can be collected from a peripheral blood draw and analyzed to isolate, enumerate, and molecularly characterize CTCs. While there is deserved excitement surrounding new CTC technologies, studies are ongoing to determine whether these cells can provide reliable and accurate information about molecular drivers of cancer progression and inform treatment decisions. This review focuses on the current status of CTCs in genitourinary (GU) cancer. We will review currently used methodologies to isolate and detect CTCs, their use as predictive biomarkers, and highlight emerging research and applications of CTC analysis in GU malignancies.
Insights
Liquid biopsies analyzing circulating tumor cells (CTCs) offer a safe alternative to invasive tumor biopsies for molecular profiling in genitourinary (GU) cancers. Ongoing research evaluates CTCs as reliable biomarkers for guiding precision cancer medicine.
Area of Science:
- Oncology
- Molecular Biology
- Genitourinary (GU) Malignancies
Background:
- Precision medicine in oncology relies on molecular profiling of tumor tissue.
- Tumor biopsies are often infeasible due to location, safety concerns, or cost.
- Circulating tumor cells (CTCs) in liquid biopsies offer a minimally invasive alternative for tissue analysis.
Purpose of the Study:
- To review the current status of CTCs in genitourinary (GU) cancer.
- To discuss methodologies for CTC isolation and detection.
- To highlight the role of CTCs as predictive biomarkers and emerging applications in GU malignancies.
Main Methods:
- Review of current literature on CTC isolation and detection techniques.
- Analysis of CTCs as predictive biomarkers in GU cancers.
- Discussion of emerging research and applications of CTC analysis.
Main Results:
- CTCs provide a viable, less invasive source for molecular analysis compared to traditional biopsies.
- CTC analysis holds promise for informing treatment decisions in GU oncology.
- Further research is needed to validate CTCs as reliable biomarkers for cancer progression.
Conclusions:
- CTCs represent a significant advancement in accessing tumor molecular information non-invasively.
- The application of CTCs in GU cancer management is expanding, offering potential for personalized treatment strategies.
- Continued investigation into CTC technologies will enhance their clinical utility in oncology.
More Related Videos
14:14Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
05:17Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
Published on: May 14, 2019
